Literature DB >> 25411763

Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.

Julio C Valencia1, Wendy K Steagall1, Yi Zhang1, Patricia Fetsch2, Andrea Abati2, Katsuya Tsukada1, Eric Billings3, Vincent J Hearing4, Zu-Xi Yu5, Gustavo Pacheco-Rodriguez1, Joel Moss6.   

Abstract

BACKGROUND: Lymphangioleiomyomatosis (LAM) is characterized by the proliferation in the lung, axial lymphatics (eg, lymphangioleiomyomas), and kidney (eg, angiomyolipomas) of abnormal smooth muscle-like LAM cells, which express melanoma antigens such as Pmel17/gp100 and have dysfunctional tumor suppressor tuberous sclerosis complex (TSC) genes TSC2 or TSC1. Histopathologic diagnosis of LAM in lung specimens is based on identification of the Pmel17 protein with the monoclonal antibody HMB-45.
METHODS: We compared the sensitivity of HMB-45 to that of antipeptide antibody αPEP13h, which reacts with a C-terminal peptide of Pmel17. LAM lung nodules were laser-capture microdissected to identify proteins by Western blotting.
RESULTS: HMB-45 recognized approximately 25% of LAM cells within the LAM lung nodules, whereas αPEP13h identified > 82% of LAM cells within these structures in approximately 90% of patients. Whereas HMB-45 reacted with epithelioid but not with spindle-shaped LAM cells, αPEP13h identified both spindle-shaped and epithelioid LAM cells, providing greater sensitivity for detection of all types of LAM cells. HMB-45 recognized Pmel17 in premelanosomal organelles; αPEP13h recognized proteins in the cytoplasm as well as in premelanosomal organelles. Both antibodies recognized a Pmel17 variant of approximately 50 kDa.
CONCLUSIONS: Based on its sensitivity and specificity, αPEP13h may be useful in the diagnosis of LAM and more sensitive than HMB-45.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25411763      PMCID: PMC4347535          DOI: 10.1378/chest.14-0380

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  43 in total

1.  Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1991-11

2.  A staining procedure for melanin in semithin and ultrathin epoxy sections.

Authors:  S G van Duinen; D J Ruiter; E Scheffer
Journal:  Histopathology       Date:  1983-01       Impact factor: 5.087

3.  Electron microscopic identification of aberrant melanosomes using a combined dopa/Warthin-Starry technique.

Authors:  A Rennison; C Duff; J L McPhie
Journal:  J Pathol       Date:  1987-08       Impact factor: 7.996

4.  Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).

Authors:  Elena A Goncharova; Dmitry A Goncharov; Andrew Eszterhas; Deborah S Hunter; Marilyn K Glassberg; Raymond S Yeung; Cheryl L Walker; Daniel Noonan; David J Kwiatkowski; Margaret M Chou; Reynold A Panettieri; Vera P Krymskaya
Journal:  J Biol Chem       Date:  2002-06-03       Impact factor: 5.157

5.  The Pmel 17/silver locus protein. Characterization and investigation of its melanogenic function.

Authors:  T Kobayashi; K Urabe; S J Orlow; K Higashi; G Imokawa; B S Kwon; B Potterf; V J Hearing
Journal:  J Biol Chem       Date:  1994-11-18       Impact factor: 5.157

6.  Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis.

Authors:  Toshio Kumasaka; Kuniaki Seyama; Keiko Mitani; Teruhiko Sato; Sanae Souma; Takashi Kondo; Seiji Hayashi; Masato Minami; Toshimasa Uekusa; Yoshinosuke Fukuchi; Koichi Suda
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

7.  In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.

Authors:  Ling Gao; Michael M Yue; Jennifer Davis; Elisabeth Hyjek; Lucia Schuger
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

8.  Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis.

Authors:  F Bonetti; P L Chiodera; M Pea; G Martignoni; F Bosi; G Zamboni; G M Mariuzzi
Journal:  Am J Surg Pathol       Date:  1993-11       Impact factor: 6.394

9.  Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment.

Authors:  Ken-ichi Yasumoto; Hidenori Watabe; Julio C Valencia; Tsuneto Kushimoto; Takeshi Kobayashi; Ettore Appella; Vincent J Hearing
Journal:  J Biol Chem       Date:  2004-04-19       Impact factor: 5.157

10.  Molecular characterization of the melanocyte lineage-specific antigen gp100.

Authors:  G J Adema; A J de Boer; A M Vogel; W A Loenen; C G Figdor
Journal:  J Biol Chem       Date:  1994-08-05       Impact factor: 5.157

View more
  4 in total

1.  CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Mary E Haughey; Patricia A Julien-Williams; Mario P Stylianou; Bernadette R Gochuico; Joel Moss
Journal:  Chest       Date:  2017-05-30       Impact factor: 9.410

2.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

3.  Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis.

Authors:  Debbie Clements; Arundhati Dongre; Vera P Krymskaya; Simon R Johnson
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

4.  Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment.

Authors:  Yi Liu; Zhibin Guo; Chenlong Zhao; Xin Li; Hongyu Liu; Jun Chen
Journal:  Onco Targets Ther       Date:  2018-08-31       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.